Human Genetic Variation and Disease
Human Genetic Variation and Disease
批准号:
10206753
负责人:
Lynn Jorde
金额:
$60.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
未结题
起止时间:
2016-07-22 至 2026-06-30
关键词:
AdultAgeAmyotrophic Lateral SclerosisBloodBlood specimenChronic Childhood ArthritisCollectionDNADNA Insertion ElementsDNA RepairDNA Repair GeneDataDetectionDiseaseEventFamilyFundingGenerationsGenesGenetic DiseasesGenetic VariationGenomeGerm-Line MutationHumanHuman GeneticsIn VitroLongevityLongitudinal StudiesMeasurementMeasuresMethodsMosaicismMutationParticipantPatternPhenotypePopulation DatabasePremature MenopauseRNA SequencesResourcesSamplingSequence AnalysisSomatic MutationSystemTestingTimeUtahVariantWhole BloodWorkanalytical toolde novo mutationgenetic informationgenetic pedigreeimprovedin vivomemberpublic repositorytranscriptome sequencingtransmission processwhole genome
中文摘要
在这次更新中,我们将继续研究人类的病因和疾病后果
遗传变异。我们已经从三代人中产生了全基因组序列(WGS)数据
犹他州CEPH家系纵向描述从头突变(DNMs)的比率和模式。我们
在不同的家庭中,突变累积的速度有显著的差异,我们
研究表明,10%的表观DNM实际上是导致嵌合体的合子后事件。我们
还表明,年龄调整的生殖系DNM传播率较高与
寿命更短,更年期更早。这些结果表明,一个人的生殖系DNM率,即
随着年龄的增长,与体细胞突变率有关。在下一个资助期,我们将测试
这一假设直接使用了在三个不同的时间点收集的血液提取的DNA样本
在35年内拥有相同的CEPH血统成员。据我们所知,这是第一个长期的
人类家系生殖系和体细胞突变率的纵向研究。我们还假设
DNA修复机制影响胚系和体细胞突变率的变异。我们将测试
这一假设使用全基因组序列数据(由单独的资金支持)和rna-seq数据。
从新采集的全血样本中。我们预测关键DNA修复的低表达
基因将导致更高的生殖系和体细胞突变率。
为了增强我们检测模式和疾病关联的能力,我们将(在单独的
资金)扩大CEPH系谱收集,以包括第四个
一代人,他们现在是成年人。我们还将第三次对第二代和第三代进行重新采样。我们会
在这些研究参与者中进行WGS和RNA-SEQ,创建一个独特的、公开可用的存储库
跨越四代人的遗传信息。进行了180多项表型测量
对于20年前的第二代和第三代CEPH家系,将进行同样的测量
这些资源将使我们能够探索遗传变异的影响,包括突变
比率和DNA修复,在几代人的广泛的表型分类。
此外,我们将继续努力开发新的和改进的基因组检测方法。
序列分析,包括检测移动元件插入。我们将分析WGS和
犹他州人群中大型犹他病家系成员的RNA-SEQ数据
数据库,重点是肌萎缩侧索硬化症和青少年特发性关节炎。这些项目
包括WGS和RNA-SEQ数据的分析以及体外和体内系统的功能分析。
英文摘要
In this renewal, we will continue our studies of the causes and disease consequences of human
genetic variation. We have generated whole-genome sequence (WGS) data from the three-generation
Utah CEPH pedigrees to longitudinally characterize rates and patterns of de novo mutations (DNMs). We
showed significant differences in the rates of accumulation of mutations among families, and we
demonstrated that 10% of apparent DNMs are actually postzygotic events that result in mosaicism. We
also showed that a higher rate of age-adjusted germline DNM transmission is significantly associated with
a shorter lifespan and earlier menopause. These results imply that one’s germline DNM rate, which
increases with age, is associated with the somatic mutation rate. In the next funding period, we will test
this hypothesis directly using blood-derived DNA samples collected at three different time points in the
same CEPH pedigree members over a 35-year time period. To our knowledge, this is the first long-term
longitudinal study of germline and somatic mutation rates in human pedigrees. We also hypothesize that
DNA repair mechanisms influence variation in both germline and somatic mutation rates. We will test
this hypothesis using whole-genome sequence data (supported by separate funding) and RNA-seq data
from freshly collected whole blood samples. We predict that lower expression of critical DNA repair
genes will result in higher germline and somatic mutation rates.
To increase our power to detect patterns and disease associations, we will (under separate
funding) expand the CEPH pedigree collection to include more than 700 members of the fourth
generation, who are now adults. We will also resample generations 2 and 3 for a third time. We will
undertake WGS and RNA-seq in these study participants, creating a unique, publicly available repository
of genetic information spanning four generations. More than 180 phenotypic measurements were made
for generations 2 and 3 of the CEPH pedigrees 20 years ago, and the same measurements will be made for
generation 4. These resources will allow us to explore the effects of genetic variation, including mutation
rates and DNA repair, on a broad assortment of phenotypes across several generations.
In addition, we will continue our work to develop new and improved methods for genome
sequence analysis, including the detection of mobile element insertions. We will analyze WGS and
RNA-seq data from members of large Utah disease pedigrees obtained from the Utah Population
Database, focusing on amyotrophic lateral sclerosis and juvenile idiopathic arthritis. These projects
involve analysis of WGS and RNA-seq data as well as functional analysis in in vitro and in vivo systems.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human Genetic Variation and Disease
-
批准号:10431948
-
项目类别:
-
资助金额:$58.3万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
Training Program in Genomic Medicine
-
批准号:10632018
-
项目类别:
-
资助金额:$30.53万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
Human Genetic Variation and Disease
-
批准号:10646423
-
项目类别:
-
资助金额:$58.3万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
Training Program in Genomic Medicine
-
批准号:10415080
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
Training Program in Genomic Medicine
-
批准号:10170829
-
项目类别:
-
资助金额:$22.66万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
Training Program in Genomic Medicine
-
批准号:9278223
-
项目类别:
-
资助金额:$30.18万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
Human Genetic Variation and Disease
-
批准号:9079187
-
项目类别:
-
资助金额:$40.69万
-
财政年份:2016
-
负责人:Lynn Jorde
-
依托单位:
VAAST+: Tool for variant prioritization, risk assessment and disease-gene finding
-
批准号:8721455
-
项目类别:
-
资助金额:$54.25万
-
财政年份:2013
-
负责人:Lynn Jorde
-
依托单位:
VAAST+: Tool for variant prioritization, risk assessment and disease-gene finding
-
批准号:8919919
-
项目类别:
-
资助金额:$52.41万
-
财政年份:2013
-
负责人:Lynn Jorde
-
依托单位:
VAAST+: Tool for variant prioritization, risk assessment and disease-gene finding
-
批准号:9551714
-
项目类别:
-
资助金额:$11.75万
-
财政年份:2013
-
负责人:Lynn Jorde
-
依托单位:
VAAST+: Tool for variant prioritization, risk assessment and disease-gene finding
-
批准号:8431204
-
项目类别:
-
资助金额:$51.66万
-
财政年份:2013
-
负责人:Lynn Jorde
-
依托单位:
The Angiotensinogen Gene and Human Hypertension
-
批准号:6997858
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2003
-
负责人:Lynn Jorde
-
依托单位:
The Angiotensinogen Gene and Human Hypertension
-
批准号:6835985
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2003
-
负责人:Lynn Jorde
-
依托单位:
The Angiotensinogen Gene and Human Hypertension
-
批准号:6699985
-
项目类别:
-
资助金额:$33.19万
-
财政年份:2003
-
负责人:Lynn Jorde
-
依托单位:
The Angiotensinogen Gene and Human Hypertension
-
批准号:6573681
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2003
-
负责人:Lynn Jorde
-
依托单位:
Population Genetics of Mobile Elements
-
批准号:7898392
-
项目类别:
-
资助金额:$53.87万
-
财政年份:1999
-
负责人:Lynn Jorde
-
依托单位:
Population Genetics of Mobile Elements
-
批准号:8245891
-
项目类别:
-
资助金额:$51.05万
-
财政年份:1999
-
负责人:Lynn Jorde
-
依托单位:
POPULATION GENETICS OF MOBILE ELEMENTS
-
批准号:2833517
-
项目类别:
-
资助金额:$46.26万
-
财政年份:1999
-
负责人:Lynn Jorde
-
依托单位:
Population Genetics of Mobile Elements
-
批准号:8437172
-
项目类别:
-
资助金额:$49.13万
-
财政年份:1999
-
负责人:Lynn Jorde
-
依托单位:
Population Genetics of Mobile Elements
-
批准号:6965467
-
项目类别:
-
资助金额:$57.52万
-
财政年份:1999
-
负责人:Lynn Jorde
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: